Zacks Investment Research downgraded shares of Valeant Pharmaceuticals (VRX) from OUTPERFORM to UNDERPERFORM on August 06, 2014, with a target price of $101.00.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Valeant Pharmaceuticals (VRX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment